For in vitro diagnostic use. Others cobas HBV Test 5800-6800-8800 IVD cobas® HBV RMD-58-68-88-HBV Quantitative nucleic acid test for use on the cobas® 5800/6800/8800 systems 09 040 820 190 9 040 820 190 09040820190 9040820190 09040820190 KIT COBAS 58/68/8800 HBV 192T IVD cobas HBV 00875197006414 Reagents, kits 1 kit 192 tests true cobas® HBV cobas® HBV is an in vitro nucleic acid amplification test for the quantitation of hepatitis B virus (HBV) DNA in human EDTA plasma or serum of HBV-infected individuals. This test is intended for use as an aid in the management of patients with chronic HBV infection undergoing anti-viral therapy. The test can be used to measure HBV DNA levels at baseline and during treatment to aid in assessing response to treatment. The results from cobas® HBV must be interpreted within the context of all relevant clinical and laboratory findings. cobas® HBV/HCV/HIV-1 Control Kit cobas® HBV/HCV/HIV-1 Control Kit is intended for use as a positive run/batch control on the cobas® 5800/6800/8800 systems with the cobas® HBV, cobas® HCV, and cobas® HIV-1 tests en cobas® HBV is an in vitro nucleic acid amplification test for the quantitation of hepatitis B virus (HBV) DNA in human EDTA plasma or serum of HBV-infected individuals.This test is intended for use as an aid in the management of patients with chronic HBV infection undergoing anti-viral therapy. The test can be used to measure HBV DNA levels at baseline and during treatment to aid in assessing response to treatment. The results from cobas® HBV must be interpreted within the context of all relevant clinical and laboratory findings.The cobas® HBV is not intended for use as a screening test for the presence of HBV in blood or blood products or as a diagnostic test to confirm the presence of HBV infection. en cobas® HBV for use on the cobas® 5800/6800/8800 Systems is an in vitro nucleic acid amplification test for the quantitation of hepatitis B virus (HBV) DNA in human EDTA plasma or serum of HBV-infected individuals.This test is intended for use as an aid in the management of patients with chronic HBV infection undergoing anti-viral therapy. The test can be used to measure HBV DNA levels at baseline and during treatment to aid in assessing response to treatment. The results from cobas® HBV must be interpreted within the context of all relevant clinical and laboratory findings. en cobas® HBV is based on fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection. The cobas® 5800 system is designed as one integrated instrument. The cobas® 6800/8800 systems consist of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the cobas® 5800 or cobas® 6800/8800 system softwares which assigns test results for all tests as target not detected, < LLoQ (lower limit of quantitation), > ULoQ (upper limit of quantitation) or HBV DNA detected, a value in the linear range LLoQ<x<ULoQ. Results can be reviewed directly on the system screen, exported, or printed as a report. Nucleic acid from patient samples, external controls and added lambda DNA (DNA-QS) molecules are simultaneously extracted. Viral nucleic acid is released by addition of proteinase and lysis reagent to the sample. The released nucleic acid binds to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured protein, cellular debris and potential PCR inhibitors are removed with subsequent wash reagent steps and purified nucleic acid is eluted from the magnetic glass particles with elution buffer at elevated temperature. Selective amplification of target nucleic acid from the sample is achieved by the use of target virus-specific forward and reverse primers which are selected from the highly conserved pre-core and core regions of HBV. Selective amplification of DNA-QS is achieved by the use of sequence-specific forward and reverse primers which are selected to have no homology with the HBV genome. A thermostable DNA polymerase enzyme is used for amplification. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythimidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon). 14,17,18 Any contaminating amplicon from previous PCR runs are eliminated by the AmpErase enzyme, which is included in the PCR mix, during the first thermal cycling step. However, newly formed amplicon are not eliminated since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C. The cobas® HBV master mix contains detection probes which are specific for the HBV target sequences and the QS nucleic acid, respectively. The specific HBV and DNA-QS detection probes are each labeled with one of two unique fluorescent dyes which acts as a reporter. Each probe also has a second dye which acts as a quencher. The two reporter dyes are measured at defined wavelengths, thus permitting simultaneous detection and discrimination of the amplified HBV target and the DNA-QS.12,13 When not bound to the target sequence, the fluorescent signal of the intact probe is suppressed by a quencher dye. During the PCR amplification step, hybridization of the probes to the specific single- stranded DNA template results in cleavage of the probe by the 5' to 3' exonuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye increases concomitantly. Since the two specific reporter dyes are measured at defined wavelengths, simultaneous detection and discrimination of the amplified HBV target and the DNA-QS are possible. 12. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (N Y). 1992;10:413-7. PMID: 1368485. 13. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-94. PMID: 8908518. 14. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene. 1990;93:125-8. PMID: 2227421. 17. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature. 1995;373:487-93. PMID: 7845459. 18. Mol CD, Arvai AS, Slupphaug G, et al. Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis. Cell. 1995;80:869-78. PMID: 7697717. en cobas® HBV is based on fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection. The cobas® 6800/8800 Systems consist of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the cobas® 6800/8800 software which assigns test results for all tests as target not detected, < LLoQ (lower limit of quantitation), > ULoQ (upper limit of quantitation) or HBV DNA detected, a value in the linear range LLoQ ≤ x ≤ ULoQ. Results can be reviewed directly on the system screen, exported, or printed as a report.Nucleic acid from patient samples, external controls and added lambda DNA (DNA-QS) molecules are simultaneously extracted.Viral nucleic acid is released by addition of proteinase and lysis reagent to the sample. The released nucleic acid binds to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured protein, cellular debris and potential PCR inhibitors are removed with subsequent wash reagent steps and purified nucleic acid is eluted from the magnetic glass particles with elution buffer at elevated temperature.Selective amplification of target nucleic acid from the sample is achieved by the use of target virus-specific forward and reverse primers which are selected from highly conserved regions of HBV. Selective amplification of DNA-QS is achieved by the use of sequence-specific forward and reverse primers which are selected to have no homology with the HBV genome. A thermostable DNA polymerase enzyme is used for amplification. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythimidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon).16,19,20 Any contaminating amplicon from previous PCR runs are eliminated by the AmpErase enzyme, which is included in the PCR mix, during the first thermal cycling step. However, newly formed amplicon are not eliminated since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C.The cobas® HBV master mix contains detection probes which are specific for the HBV target sequences and the QS nucleic acid, respectively. The specific HBV and DNA-QS detection probes are each labeled with one of two unique fluorescent dyes which acts as a reporter. Each probe also has a second dye which acts as a quencher. The two reporter dyes are measured at defined wavelengths, thus permitting simultaneous detection and discrimination of the amplified HBV target and the DNA-QS.14,15 When not bound to the target sequence, the fluorescent signal of the intact probe is suppressed by a quencher dye. During the PCR amplification step, hybridization of the probes to the specific single- stranded DNA template results in cleavage of the probe by the 5' to 3' exonuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye increases concomitantly. Since the two specific reporter dyes are measured at defined wavelengths, simultaneous detection and discrimination of the amplified HBV target and the DNA-QS are possible.14. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (N Y). 1992;10:413-7. PMID: 1368485.15. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-94. PMID: 8908518.16. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene. 1990;93:125-8. PMID: 2227421.19. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature. 1995;373:487-93. PMID: 7845459.20. Mol CD, Arvai AS, Sanderson RJ, et al. Crystal structure of human uracil-DNA glycosylase in complex with a protein inhibitor: protein mimicry of DNA. Cell. 1995;82:701-8. PMID: 7671300. en cobas® HBV is based on fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection. The cobas® 6800/8800 Systems consist of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the cobas® 6800/8800 software which assigns test results for all tests as target not detected, < LLoQ (lower limit of quantitation), > ULoQ (upper limit of quantitation) or HBV DNA detected, a value in the linear range LLoQ ≤ x ≤ ULoQ. Results can be reviewed directly on the system screen, exported, or printed as a report.Nucleic acid from patient samples, external controls and added lambda DNA (DNA-QS) molecules are simultaneously extracted.Viral nucleic acid is released by addition of proteinase and lysis reagent to the sample. The released nucleic acid binds to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured protein, cellular debris and potential PCR inhibitors are removed with subsequent wash reagent steps and purified nucleic acid is eluted from the magnetic glass particles with elution buffer at elevated temperature.Selective amplification of target nucleic acid from the sample is achieved by the use of target virus-specific forward and reverse primers which are selected from highly conserved regions of HBV. Selective amplification of DNA-QS is achieved by the use of sequence-specific forward and reverse primers which are selected to have no homology with the HBV genome. A thermostable DNA polymerase enzyme is used for amplification. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythimidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon).14,17,18 Any contaminating amplicon from previous PCR runs are eliminated by the AmpErase enzyme, which is included in the PCR mix, during the first thermal cycling step. However, newly formed amplicon are not eliminated since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C.The cobas® HBV master mix contains detection probes which are specific for the HBV target sequences and the QS nucleic acid, respectively. The specific HBV and DNA-QS detection probes are each labeled with one of two unique fluorescent dyes which acts as a reporter. Each probe also has a second dye which acts as a quencher. The two reporter dyes are measured at defined wavelengths, thus permitting simultaneous detection and discrimination of the amplified HBV target and the DNA-QS.12,13 When not bound to the target sequence, the fluorescent signal of the intact probe is suppressed by a quencher dye. During the PCR amplification step, hybridization of the probes to the specific single- stranded DNA template results in cleavage of the probe by the 5' to 3' exonuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye increases concomitantly. Since the two specific reporter dyes are measured at defined wavelengths, simultaneous detection and discrimination of the amplified HBV target and the DNA-QS are possible.12. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (N Y). 1992;10:413-7. PMID: 1368485.13. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-94. PMID: 8908518.14. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene. 1990;93:125-8. PMID: 2227421.17. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature. 1995;373:487-93. PMID: 7845459.18. Mol CD, Arvai AS, Slupphaug G, et al. Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis. Cell. 1995;80:869-78. PMID: 7697717 en

cobas^® HBV

Xét nghiệm định lượng acid nucleic sử dụng trên hệ thống cobas^® 5800/6800/8800

IVD

Liên hệ chúng tôi

Thông tin chung

Tổng quan

HBV là một trong các vi rút gây bệnh viêm gan do vi rút. Hơn 2 tỉ người trên trên toàn thế giới đã phơi nhiễm với HBV và trên 350 triệu người là người mang vi rút mạn tính.¹ HBV là nguyên nhân chính gây bệnh gan ở Mỹ, mặc dù tỷ lệ nhiễm cấp đang giảm dần nhờ tiêm vắc xin và áp dụng các biện pháp an toàn khi tiêm.² Tỷ lệ hiện mắc ở Mỹ được ước tính khoảng từ 0.3% đến 0.5%, với 47% đến 70% các trường hợp là người được sinh ở ngoài nước Mỹ.² Tuy nhiên, các chương trình sàng lọc đã cho thấy tỷ lệ nhiễm là trên 15% ở nhóm dân nhập cư có nguy cơ cao.³ Bệnh nhân nhiễm HBV mạn tính có nguy cơ cao bị các biến chứng lâu dài, bao gồm viêm gan mạn tính, xơ gan và ung thư biểu mô tế bào gan.^4-7 Các dấu ấn huyết thanh học thường được sử dụng làm các chỉ dấu chẩn đoán và/hoặc tiên lượng cho nhiễm HBV cấp tính hoặc mạn tính.⁸ Trung tâm kiểm soát và phòng ngừa dịch bệnh của Hoa Kỳ mở rộng các khuyến cáo cho sàng lọc thường quy những người có nguy cơ cao đến nay bao gồm sàng lọc trong dân số có tỷ lệ kháng nguyên bề mặt HBV (HBsAg) trên 2% bao gồm những người đến từ các vùng lưu hành bệnh của thế giới (như Châu Á và Châu Phi), nam giới có quan hệ tình dục cùng giới và người tiêm chích ma túy.² Dấu ấn phổ biến nhất của nhiễm HBV là sự hiện diện của HBsAg.⁸ Mặc dù những người mang vi rút có thể không còn HBsAg và tạo kháng thể kháng HBsAg, nhưng vẫn có thể xuất hiện nguy cơ biến chứng gan nặng sau đó.^9,10

Kháng nguyên HBe (HBeAg) thường được sử dụng như là một dấu ấn thứ hai cho sự sao chép HBV đang hoạt động có liên quan đến bệnh gan tiến triển. Việc HBeAg trong máu không được loại trừ có khả năng làm tăng nguy cơ dẫn đến bệnh gan giai đoạn cuối.^9,10 Các chủng biến thể HBV đột biến tiền lõi có thể mất khả năng sản xuất HBeAg ngay cả khi tình trạng nhiễm đang hoạt động, do đó giới hạn việc sử dụng dấu ấn này để theo dõi tiến triển bệnh.⁷

Mục đích sử dụng

cobas^® HBV

Xét nghiệm cobas^® HBV là một xét nghiệm khuếch đại acid nucleic in vitro để định lượng DNA của vi rút viêm gan B (HBV) trong huyết tương chống đông bằng EDTA hoặc huyết thanh của người bị nhiễm HBV.

Xét nghiệm này được chỉ định hỗ trợ theo dõi bệnh nhân nhiễm HBV mạn tính đang điều trị bằng thuốc kháng vi rút. Xét nghiệm này có thể được sử dụng để đo nồng độ DNA HBV ở đường nền và trong quá trình điều trị để hỗ trợ đánh giá đáp ứng điều trị. Kết quả từ xét nghiệm cobas^® HBV phải được biện luận trong bối cảnh tất cả các kết quả lâm sàng và xét nghiệm có liên quan.

cobas^® HBV/HCV/HIV-1 Control Kit

cobas^® HBV/HCV/HIV-1 Control Kit được sử dụng là mẫu chứng dương cho mẻ chạy trên các hệ thống cobas^® 5800/6800/8800 cho các xét nghiệm cobas^® HBV, cobas^® HCV, và cobas^® HIV-1.

Thông tin chung

Thông tin đặt hàng

Hệ thống xét nghiệm tương thích

Liên hệ

Nếu bạn có câu hỏi về các sản phẩm hoặc dịch vụ của chúng tôi, vui lòng điền vào biểu mẫu.
Đại diện kinh doanh của Roche sẽ liên hệ với bạn.

Tài liệu tham khảo:

Custer B, Sullivan SD, Hazlet TK, et al. Global epidemiology of hepatitis B virus. J Clin Gastroenterol. 2004;38:S158-68. PMID: 15602165.
Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57:1-20. PMID: 18802412.
Hu KQ. Hepatitis B virus (HBV) infection in Asian and Pacific Islander Americans (APIAs): how can we do better for this special population? Am J Gastroenterol. 2008;103:1824-33. PMID: 18479498.
Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486-500. PMID: 18832247.
Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009;29 Suppl 1:100-7. PMID: 19207972.
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335-52. PMID: 18096267.
But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol. 2008;14:1652-6. PMID: 18350595.
Kao JH. Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Rev Gastroenterol Hepatol. 2008;2:553-62. PMID: 19072403.
Yuen MF, Wong DK, Fung J, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135:1192-9. PMID: 18722377.
Tong MJ, Hsien C, Song JJ, et al. Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis. Dig Dis Sci. 2009;54:1337-46. PMID: 19242792.

Thông tin đăng ký sản phẩm:

Thuốc thử xét nghiệm định lượng DNA HBV

cobas^® HBV

Vật liệu kiểm soát dương tính xét nghiệm định tính và định lượng RNA HIV-1, định lượng DNA HBV, định tính và định lượng RNA HCV

cobas^® HBV/HCV/HIV-1 Control Kit

Chủ sở hữu số lưu hành:

CÔNG TY TNHH ROCHE VIỆT NAM

Tầng 27, Tòa nhà Pearl Plaza, 561A Điện Biên Phủ, Phường Thạnh Mỹ Tây, Tp. Hồ Chí Minh, Việt Nam

Mã số tài liệu: MC-VN-01642

User profile

Select your user profile

cobas^® HBV

Thông tin chung

Thông tin chung

Thông tin đặt hàng

Tài liệu kỹ thuật

Truy cập các tài liệu sẵn có tại quốc gia của bạn

Hệ thống xét nghiệm tương thích

Liên hệ

User profile

Select your user profile

cobas® HBV

Thông tin chung

Thông tin chung

Thông tin đặt hàng

Tài liệu kỹ thuật

Truy cập các tài liệu sẵn có tại quốc gia của bạn

Hệ thống xét nghiệm tương thích

Sản phẩm liên quan

Liên hệ

cobas^® HBV